Oramed Pharmaceuticals (NASDAQ: ORMP) — Perfil da empresa, notícias e dados financeiros
Oramed Pharmaceuticals develops oral drug delivery systems, including an innovative oral insulin capsule for diabetes.
Oramed Pharmaceuticals
Oramed Pharmaceuticals (NASDAQ:ORMP) is a biotech firm focused on the development of oral drug delivery systems, including an innovative oral insulin capsule designed to improve the treatment and management of diabetes. The company's groundbreaking approach aims to replace injectable treatments with oral alternatives, fundamentally changing the way chronic diseases are managed. Their portfolio also explores similar technologies for other medications requiring injections, with the ultimate goal of enhancing patient convenience, compliance, and overall health outcomes. Oramed Pharmaceuticals is committed to advancing these projects through clinical trials and partnerships, with the objective of making oral medication options available to a broader patient population worldwide.
Resumo
Operações
Produtos e/ou serviços de Oramed Pharmaceuticals
- An oral insulin capsule (ORMD-0801) for type 2 diabetes, aimed at replacing daily injections.
- An oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes, offering a needle-free GLP-1 therapy option.
- A combination oral insulin and GLP-1 analog capsule, designed to simultaneously address blood sugar control and weight loss in diabetic patients.
- NASH (Non-alcoholic steatohepatitis) treatment research, focusing on the application of its oral delivery technology to treat this liver disease.
- An oral vaccine delivery platform, which seeks to revolutionize the way vaccines are administered by enabling oral ingestion instead of injections.
- Development of an oral Protease Inhibitor therapy aimed at treating various conditions, leveraging their platform technology for non-injectable drug delivery.
equipe executiva do Oramed Pharmaceuticals
- Nadav KidronPresident, CEO & Executive Chairman
- Joshua HexterChief Operating & Business Officer
- Miriam KidronChief Scientific Officer & Director
- Avraham GabayCFO, Treasurer & Secretary
Histórico de dividendos
Dividendos por ação pagos pela Oramed Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.2500 |
Principais indicadores financeiros
Resultados divulgados pela Oramed Pharmaceuticals, em USD.
- Cap. de mercado
- 173 mi
- Receita (TTM)
- 0
- P/L
- 1.0
- LPA (diluído, TTM)
- 4.1
- Dividend yield
- 0.0%
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2 mi | -15,1 mi | 64,1 mi | |
| 0 | -12,8 mi | -19,1 mi | |
| 1,3 mi | -15,8 mi | 5,5 mi | |
| 2,7 mi | -40,6 mi | -37,8 mi |